Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Lowers Price Target to $1.5
Wells Fargo analyst Nick Abbott maintains Adaptimmune Therapeutics (NASDAQ:ADAP) with a Equal-Weight and lowers the price target from $7 to $1.5.
Important Biotech Catalysts For September 9, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to…
Adaptimmune Reported 44% Objective Response Rate With a Single Dose of ADP-A2M4CD8 in 25 Heavily Pre-treated Patients With Late-stage Ovarian, Urothelial, and Head & Neck Cancers
Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces positive data from its signal-finding Phase 1 SURPASS trial.
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.